Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Free Cash Flow (2021 - 2024)

Opus Genetics (IRD) has disclosed Free Cash Flow for 8 consecutive years, with $4.5 million as the latest value for Q4 2023.

  • On a quarterly basis, Free Cash Flow fell 84.2% to $4.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$1.1 million, a 107.77% decrease, with the full-year FY2024 number at -$25.6 million, down 2200.0% from a year prior.
  • Free Cash Flow was $4.5 million for Q4 2023 at Opus Genetics, up from -$3.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $28.8 million in Q4 2022 to a low of -$6.2 million in Q1 2022.
  • A 3-year average of -$47454.5 and a median of -$3.6 million in 2023 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 125.96% in 2023; the steepest drop was 84.2% in 2023.
  • Opus Genetics' Free Cash Flow stood at -$3.6 million in 2021, then surged by 903.32% to $28.8 million in 2022, then crashed by 84.2% to $4.5 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Free Cash Flow are $4.5 million (Q4 2023), -$3.0 million (Q3 2023), and $989000.0 (Q2 2023).